Leading Innovation in Diabetes Care and Treatment| Sanofi
WEBFor 100 years, our innovations have helped define the standard of care for people living with diabetes. We are not done. Looking to the future, we want to help bring diabetes under control with our medicines, education programs, services, apps, and connected devices.
Diabetes - Sanofi
WEBOur aim is to transform the way diabetes is managed and treated, not just with medicines, but with a holistic approach to managing the condition. We believe diabetes education is critical for individuals living with the condition and for the healthcare professionals who care for them. See more.
Our Products and Resources | Sanofi USA
WEBSanofi is a diversified global healthcare leader, focused on developing products that meet the health needs of people. We have extensive lines of prescription medicines and vaccines, as well as consumer health products. Prescription Products. Vaccine Products.
Exploring Our Prescription Product Information | Sanofi USA
WEBZaltrap® (ziv-aflibercept) Injection for intravenous infusion. Explore Sanofi's comprehensive list of prescription product information, tailored to meet diverse healthcare needs.
FDA approves first treatment to delay onset of type 1 diabetes
WEBNov 17, 2022 · The monoclonal antibody teplizumab, which will be marketed under the brand name Tzield, from ProventionBio and Sanofi is given through intravenous infusion.
Sanofi Pipeline: Discover Our R&D Projects
WEBJul 25, 2024 · Our determination to find answers for patients and their families motivates us to pursue medicines and vaccines with the greatest potential to improve lives and protect public health. With a strong focus on difficult-to-treat diseases and immunization, our R&D pipeline includes 78 clinical-stage projects, 33 of which are in phase 3 or have been ...
New Soliqua®* data shows improved blood sugar control without ... - Sanofi
WEBJun 28, 2014 · A new study of Soliqua (insulin glargine 100 Units/mL and lixisenatide, iGlarLixi) met its two primary endpoints and all key secondary endpoints in a head-to-head comparison against premixed insulin (biphasic insulin aspart 30, BIAsp 30) in adults living with type 2 diabetes, the most common form of diabetes, uncontrolled on …
Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes
WEBOct 18, 2023 · Teplizumab, a humanized monoclonal antibody to CD3 on T cells, is approved by the Food and Drug Administration to delay the onset of clinical type 1 diabetes (stage 3) in patients 8 years of age...
Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes …
WEBAug 22, 2023 · In November 2022, teplizumab-mzwv (TZIELD; Provention Bio, Inc., a Sanofi Company, Red Bank, NJ) became the first drug approved to change the progression of autoimmunity in type 1 diabetes (i.e., to delay the onset of stage 3 type 1 diabetes in adults and children age ≥8 years with stage 2 disease).
Sanofi Receives FDA Approval of AdlyxinTM for Treatment of …
WEBPARIS, July 27, 2016 /PRNewswire/ -- Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved Adlyxin™ (lixisenatide), a once-daily mealtime GLP-1 receptor agonist injection indicated as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes.